Background: Overactive bladder (OAB) is a common syndrome that can negatively affect patients’ daily activities, sleep patterns, mental health, sexual function, and general health. In addition to reducing the frequency of attacks, treatment of OAB can be expected to improve the psychological and sexual health of patients. Aims: To evaluate the effects of mirabegron used in the treatment of overactive bladder (OAB) on female sexual function (FSF). Methods: This retrospective study includes 48 sexually active women who were diagnosed with overactive bladder and treated with a daily oral dose of 50 mg mirabegron between November 2021 and March 2022. The evaluation of FSF was conducted using female sexual function index (FSFI) along with urinary parameters before the start of the treatment and at the 6th week of the treatment. Results: In the study, out of 48 participants, 40 (83.3%) were identified with the dry type and 8 (16.7%) with the wet type OAB. The median age when diagnosed was 43.5 years. Although the decrease in the Overactive Bladder Questionnaire (OAB-V8) score did not reach statistical significance in the entire patient group after treatment ( p = 0.058), a statistically significant decrease in the International Consultation on Incontinence Questionnaire–Short Form (ICIQ-SF) score was detected in the wet type OAB group ( p < 0.001). During the assessment of sexual function, there was a statistically significant increase in the FSFI score, from 21.4 to 23.05, by the 6th week of treatment ( p = 0.017). Specifically, the scores for desire, lubrication, and satisfaction showed a statistically significant post-treatment improvement ( p < 0.001, p = 0.049, and p = 0.035, respectively). Conclusion: The study indicates that a 6-week regimen of a daily 50 mg mirabegron dose enhanced sexual function in women. This beneficial impact of mirabegron on sexual health should be taken into account when selecting a treatment for OAB.

Purpose: Fluoroscopy is commonly used during Percutaneous Nephrolithotomy (PCNL) for renal access and tract dilatation; however, it is associated with radiation exposure for both patients and surgical staff. Strategies to minimize exposure include reducing fluoroscopy time, which serves as a surrogate marker of radiation dose. This study aims to examine the effect of reducing fluoroscopy time using intermittent fluoroscopy on treatment and perioperative outcomes in supine PCNL. Methods: We retrospectively analyzed data from 446 patients who underwent supine PCNL between April 2021 and August 2025. After applying exclusion criteria, 392 patients were included. Two experienced surgeons performed or supervised the procedures, one utilizing intermittent fluoroscopy and the other live fluoroscopy. Baseline demographics, stone characteristics, operative variables, fluoroscopy time, stone-free rates (SFR), complications, and hospital stay were compared. Propensity score matching (PSM) was conducted to minimize group baseline differences. Results: Before matching, 310 patients underwent intermittent fluoroscopy, and 82 underwent live fluoroscopy. After PSM, 82 patients remained in each group with comparable demographics and stone characteristics. Median fluoroscopy time was significantly lower in the intermittent group (25.5 s [IQR: 18–35.25]) compared with the live group (267 s [IQR: 182.5–314]; p < 0.001). Stone-free rates were similar (79.3% vs. 81.7%; p = 0.694), as were operative time, hospital stay, and complication rates(all p > 0.05). Conclusion: Intermittent fluoroscopy during supine PCNL substantially reduces fluoroscopy time without compromising stone-free rates, operative outcomes, or complication rates. This approach may be considered a safer alternative for minimizing radiation exposure to patients and healthcare providers.